Stereotaxis to Report First Quarter 2025 Financial Results on May 12, 2025
Stereotaxis (NYSE: STXS), a pioneer in surgical robotics for minimally invasive endovascular intervention, has scheduled its first quarter 2025 financial results release for May 12, 2025 after U.S. market close. The company will host a conference call and webcast at 4:30 p.m. EST to discuss results and corporate developments.
Investors can access the live call by dialing 800-715-9871 (US/Canada) or 1-646-307-1963 (International) with pass code 4794777. A webcast will be available through the investor relations section of Stereotaxis' website, with replay access available for one month after the call.
Stereotaxis' technology has been utilized in treating over 150,000 patients globally across the United States, Europe, Asia, and other regions.
Stereotaxis (NYSE: STXS), pioniere nella robotica chirurgica per interventi endovascolari minimamente invasivi, ha programmato la pubblicazione dei risultati finanziari del primo trimestre 2025 per il 12 maggio 2025 dopo la chiusura del mercato statunitense. La società terrà una conference call e una webcast alle 16:30 EST per discutere i risultati e gli sviluppi aziendali.
Gli investitori potranno partecipare alla chiamata in diretta componendo il numero 800-715-9871 (USA/Canada) o 1-646-307-1963 (Internazionale) con il codice di accesso 4794777. La webcast sarà disponibile nella sezione relazioni con gli investitori del sito web di Stereotaxis, con la possibilità di riascolto per un mese dopo la chiamata.
La tecnologia di Stereotaxis è stata utilizzata per trattare oltre 150.000 pazienti in tutto il mondo, negli Stati Uniti, Europa, Asia e altre regioni.
Stereotaxis (NYSE: STXS), pionero en robótica quirúrgica para intervenciones endovasculares mínimamente invasivas, ha programado la publicación de sus resultados financieros del primer trimestre de 2025 para el 12 de mayo de 2025 después del cierre del mercado estadounidense. La compañía realizará una conferencia telefónica y una transmisión en vivo a las 4:30 p.m. EST para discutir los resultados y desarrollos corporativos.
Los inversores pueden acceder a la llamada en vivo marcando 800-715-9871 (EE.UU./Canadá) o 1-646-307-1963 (Internacional) con el código de acceso 4794777. La transmisión estará disponible en la sección de relaciones con inversionistas del sitio web de Stereotaxis, con acceso a la repetición durante un mes después de la llamada.
La tecnología de Stereotaxis se ha utilizado para tratar a más de 150,000 pacientes en todo el mundo, incluyendo Estados Unidos, Europa, Asia y otras regiones.
Stereotaxis (NYSE: STXS)는 최소 침습성 혈관내 수술용 로봇 분야의 선구자로, 2025년 1분기 재무 실적 발표를 2025년 5월 12일 미국 시장 마감 후에 예정하고 있습니다. 회사는 오후 4시 30분(동부 표준시)에 실적 및 기업 현황을 논의하는 컨퍼런스 콜과 웹캐스트를 진행할 예정입니다.
투자자는 800-715-9871 (미국/캐나다) 또는 1-646-307-1963 (국제) 번호로 접속하며, 접속 코드 4794777를 입력해 라이브 콜에 참여할 수 있습니다. 웹캐스트는 Stereotaxis 투자자 관계 웹사이트 섹션에서 제공되며, 콜 종료 후 한 달간 다시보기 서비스를 이용할 수 있습니다.
Stereotaxis의 기술은 미국, 유럽, 아시아 및 기타 지역에서 전 세계 150,000명 이상의 환자 치료에 사용되었습니다.
Stereotaxis (NYSE : STXS), pionnier de la robotique chirurgicale pour les interventions endovasculaires peu invasives, a prévu la publication de ses résultats financiers du premier trimestre 2025 pour le 12 mai 2025 après la clôture du marché américain. La société organisera une conférence téléphonique et un webcast à 16h30 EST pour discuter des résultats et des évolutions de l'entreprise.
Les investisseurs peuvent accéder à l'appel en direct en composant le 800-715-9871 (États-Unis/Canada) ou le 1-646-307-1963 (international) avec le code d'accès 4794777. Un webcast sera disponible dans la section relations investisseurs du site web de Stereotaxis, avec un accès en replay pendant un mois après l'appel.
La technologie de Stereotaxis a été utilisée pour traiter plus de 150 000 patients dans le monde, notamment aux États-Unis, en Europe, en Asie et dans d'autres régions.
Stereotaxis (NYSE: STXS), ein Pionier in der chirurgischen Robotik für minimalinvasive endovaskuläre Eingriffe, hat die Veröffentlichung der Finanzergebnisse für das erste Quartal 2025 für den 12. Mai 2025 nach Börsenschluss in den USA geplant. Das Unternehmen wird um 16:30 Uhr EST eine Telefonkonferenz und einen Webcast abhalten, um die Ergebnisse und Unternehmensentwicklungen zu besprechen.
Investoren können den Live-Anruf unter der Nummer 800-715-9871 (USA/Kanada) oder 1-646-307-1963 (international) mit dem Zugangscode 4794777 verfolgen. Ein Webcast wird im Investor-Relations-Bereich der Stereotaxis-Website verfügbar sein, mit einer Wiedergabemöglichkeit für einen Monat nach dem Anruf.
Die Technologie von Stereotaxis wurde weltweit bei der Behandlung von über 150.000 Patienten in den USA, Europa, Asien und anderen Regionen eingesetzt.
- None.
- None.
ST. LOUIS, April 22, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financial results for its 2025 first quarter on Monday, May 12, 2025 at the close of the U.S. financial markets. The Company will host a conference call and webcast at 4:30 p.m. EST that day to discuss the Company’s results and corporate developments.
| What: | Stereotaxis first quarter 2025 financial results conference call |
| When: | Monday, May 12, 2025, at 4:30 p.m. ET (1:30 p.m. PT) |
| Dial In Number: | To access the live call, dial 800-715-9871 (US and Canada) or 1-646-307-1963 (International) and give the participant pass code 4794777. |
| Webcast: | To access the live and replay webcast, please visit the investor relations section of Stereotaxis’ website at http://ir.stereotaxis.com/. |
| Call Replay: | A phone replay of the call will be available for one month beginning approximately four hours following the end of the call. To request access for a replay of the conference call, please click here. |
About Stereotaxis
Stereotaxis (NYSE: STXS) is a pioneer and global leader in innovative surgical robotics for minimally invasive endovascular intervention. Its mission is the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide unsurpassed patient care with robotic precision and safety, expand access to minimally invasive therapy, and enhance the productivity, connectivity, and intelligence in the operating room. Stereotaxis technology has been used to treat over 150,000 patients across the United States, Europe, Asia, and elsewhere. For more information, please visit www.stereotaxis.com.
Investor Contacts: David L. Fischel Chairman and Chief Executive Officer Kimberly Peery Chief Financial Officer 314-678-6100 Investors@Stereotaxis.com
FAQ
When will Stereotaxis (STXS) release Q1 2025 earnings?
How can investors access the Stereotaxis (STXS) Q1 2025 earnings call?
How many patients have been treated with Stereotaxis (STXS) technology?
What is Stereotaxis (STXS) primary business focus?
